Background. The prostate-specific antigen (PSA) has been widely used in screening and early diagnosis of prostate cancer (PCa). However, in the PSA grey zone of 4-10 ng/ml, the sensitivity and specificity for diagnosing PCa are limited, resulting in considerable number of unnecessary and invasive prostate biopsies, which may lead to potential overdiagnosis and overtreatment.
Axumin is an FDA-approved, Medicare-covered scan that can achieve early detection of recurrent prostate cancer after surgery or radiation. For years we have been able to detect prostate cancer recurrences with PSA, but standard body and bone scans have been unable to determine the location of the cancer until the PSA level is excessively elevated (10 to 30 or higher
In fact, studies have shown that about 70% to 80% of men with an elevated PSA who have a biopsy do not have cancer. However, many men undergo an ultrasound and prostate biopsy, to be certain. Conversely, the PSA test doesn't detect all cancers. About 20% of men who have cancer also have a normal PSA (less than 4 ng/ml), so the test may give
In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic prostate cancer and died of the disease; after the introduction of the serum PSA test, randomized controlled
The PROMIS study showed the TRUS biopsy sensitivity was 48% and the true Klein E. Trends in PSA, age and prostate cancer detection among black and white men from 1990-2006 at a tertiary care
Prostate-specific antigen (PSA) is a highly sensitive serum biomarker that has changed the management of prostate cancer over the past 20 years by allowing clinicians to detect prostate cancer earlier. However, PSA testing is not perfect, as indicated by the US Preventive Services Task Force's recent recommendation against using it for routine prostate cancer screening.
6goTzs. lm7ar6d9kz.pages.dev/231lm7ar6d9kz.pages.dev/398lm7ar6d9kz.pages.dev/187lm7ar6d9kz.pages.dev/259lm7ar6d9kz.pages.dev/361lm7ar6d9kz.pages.dev/291lm7ar6d9kz.pages.dev/68lm7ar6d9kz.pages.dev/201lm7ar6d9kz.pages.dev/362
sensitivity of psa test for prostate cancer
